Close Menu

This article has been updated to clarify Natera's actions after it refiled its motion to invalidate CareDx's patents in April, as well as to correct a statement on John Quackenbush's views of the claims asserted in Stanford's patents.

NEW YORK – The United States District Court for the District of Delaware has denied a motion made by Natera to declare invalid three patents held by Stanford University and licensed exclusively to CareDx.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Researchers are developing a breath test to determine how severe patients' methylmalonic acidemia disease is, FierceBiotech reports.

NPR reports that vaccine developers are working on SARS-CoV-2 vaccines that are easier to store or administer than the current crop.

Reuters reports that France is to recommend that people under 55 who received one dose of AstraZeneca's SARS-CoV-2 vaccine receive a different vaccine for their second dose.